Collection of efficacy and safety data of chinese patients who have received Faslodex 250mg treatment

This study is a post-authorisation pharmacoepidemiology study, committed to Center for Drug Evaluation (CDE) and State Food and Drug Administration (SFDA), in order to provide more efficacy and safety data about Faslodex 250mg in real life clinical practice in China. The objective of the post marketing study is to explore the efficacy and tolerability of Fulvestrant (FASLODEX™)250 mg in postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-estrogen therapy or disease progression on therapy with an anti-estrogen.

A Multicenter, non-interventional, prospective study to collect efficacy and safety data in Chinese patients who have received Faslodex 250mg treatment under the condition of actual usage in clinical practice